Repaglinidum [Inn-Latin]
Categoria
Repaglinidum [Inn-Latin] Marchi, Repaglinidum [Inn-Latin] Analoghi
Repaglinidum [Inn-Latin] Marchi miscela
Repaglinidum [Inn-Latin] Formula chimica
C27H36N2O4
Repaglinidum [Inn-Latin] RX link
http://www.rxlist.com/cgi/generic/prandin.htm
Repaglinidum [Inn-Latin] FDA foglio
Repaglinidum [Inn-Latin] DMS (foglio di materiale di sicurezza)
Repaglinidum [Inn-Latin] Sintesi di riferimento
W. Grell et al. Int. PCT. pat. Appl. WO 93 00337
Repaglinidum [Inn-Latin] Peso molecolare
452.586 g/mol
Repaglinidum [Inn-Latin] Temperatura di fusione
130-131 oC
Repaglinidum [Inn-Latin] H2O Solubilita
Nessuna informazione disponibile
Repaglinidum [Inn-Latin] Stato
Solid
Repaglinidum [Inn-Latin] LogP
5.798
Repaglinidum [Inn-Latin] Forme di dosaggio
Compressa
Repaglinidum [Inn-Latin] Indicazione
Per il trattamento del diabete mellito di tipo II.
Repaglinidum [Inn-Latin] Farmacologia
La repaglinide è un orale di glucosio nel sangue farmaco che riduce della classe meglitinide utilizzato nella gestione del diabete di tipo 2 (noto anche come diabete non insulino-dipendente o NIDDM mellito). Repaglinide abbassa i livelli di glucosio nel sangue stimolando il rilascio di insulina dal pancreas. Questa azione è dipende dal funzionamento delle cellule beta nelle isole pancreatiche. Rilascio di insulina glucosio-dipendente è e diminuisce a basse concentrazioni di glucosio.
Repaglinidum [Inn-Latin] Assorbimento
Rapido (biodisponibilità è del 56%)
Repaglinidum [Inn-Latin] Tossicita
LD50> 1 g / kg (ratto) (W. Grell)
Repaglinidum [Inn-Latin] Informazioni paziente
PATIENT INFORMATION
Patients should be informed of the potential risks and advantages of Repaglinide (PRANDIN) and of alternative modes of therapy. They should also be informed about the importance of adherence to dietary instructions, of a regular exercise program, and of regular testing of blood glucose and HbA1c. The risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development and concomitant administration of other glucose-lowering drugs should be explained to patients and responsible family members. Primary and secondary failure should also be explained.
Patients should be instructed to take Repaglinide before meals (2, 3, or 4 times a day preprandially). Doses are usually taken within 15 minutes of the meal but time may vary from immediately preceding the meal to as long as 30 minutes before the meal. Patients who skip a meal (or add an extra meal) should be instructed to skip (or add) a dose for that meal.
Patients should be informed of the potential risks and advantages of Repaglinide (PRANDIN) and of alternative modes of therapy. They should also be informed about the importance of adherence to dietary instructions, of a regular exercise program, and of regular testing of blood glucose and HbA1c. The risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development and concomitant administration of other glucose-lowering drugs should be explained to patients and responsible family members. Primary and secondary failure should also be explained.
Patients should be instructed to take Repaglinide before meals (2, 3, or 4 times a day preprandially). Doses are usually taken within 15 minutes of the meal but time may vary from immediately preceding the meal to as long as 30 minutes before the meal. Patients who skip a meal (or add an extra meal) should be instructed to skip (or add) a dose for that meal.
Repaglinidum [Inn-Latin] Atto interessato organismi
Gli esseri umani e altri mammiferi
![Repaglinidum_[Inn-Latin]](/images/rx/APRD00439.gif)
